{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:21:49Z","timestamp":1763140909547,"version":"3.37.3"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,5]],"date-time":"2018-04-05T00:00:00Z","timestamp":1522886400000},"content-version":"vor","delay-in-days":369,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["F30 CA199962"],"award-info":[{"award-number":["F30 CA199962"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32 GM65841"],"award-info":[{"award-number":["T32 GM65841"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007048","name":"Mayo Foundation for Medical Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007093","name":"Richard M. Schulze Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA108961","R01CA175386"],"award-info":[{"award-number":["R01CA108961","R01CA175386"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ymthe.2017.01.023","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T23:16:50Z","timestamp":1487805410000},"page":"962-975","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy"],"prefix":"10.1016","volume":"25","author":[{"given":"Kevin G.","family":"Shim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Kottke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Evgin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karishma R.","family":"Rajani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Schuelke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher B.","family":"Driscoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Huff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose S.","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard G.","family":"Vile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2017.01.023_bib1","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2017.01.023_bib2","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/mt.2014.34","article-title":"The strength of the T\u00a0cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control","volume":"22","author":"Janelle","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.01.023_bib3","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.2147\/OTT.S63049","article-title":"Oncolytic viruses as immunotherapy: progress and remaining challenges","author":"Aurelian","year":"2016","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.ymthe.2017.01.023_bib4","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/hum.2010.216","article-title":"Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus","volume":"22","author":"Wongthida","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2017.01.023_bib5","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1158\/0008-5472.CAN-12-0600","article-title":"Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer","volume":"72","author":"Rommelfanger","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2017.01.023_bib6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nbt.2157","article-title":"Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma","volume":"30","author":"Pulido","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2017.01.023_bib7","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/nm.2390","article-title":"Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors","volume":"17","author":"Kottke","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2017.01.023_bib8","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/mt.2009.95","article-title":"Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity","volume":"17","author":"Boudreau","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.01.023_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2017.01.023_bib10","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T\u00a0cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2017.01.023_bib11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2017.01.023_bib12","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T\u00a0cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2017.01.023_bib13","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/blood-2015-06-652503","article-title":"Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia","volume":"127","author":"Shen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.01.023_bib14","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1158\/0008-5472.CAN-15-3130","article-title":"CD27 agonism plus PD-1 blockade recapitulates CD4+ T-cell help in therapeutic anticancer vaccination","volume":"76","author":"Ahrends","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2017.01.023_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/2326-6066.CIR-14-0126","article-title":"Vaccines combined with immune checkpoint antibodies promote cytotoxic T-cell activity and tumor eradication","volume":"4","author":"Ali","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2017.01.023_bib16","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular signature of CD8+ T\u00a0cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2017.01.023_bib17","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.immuni.2011.06.015","article-title":"Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T\u00a0cells","volume":"35","author":"Youngblood","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2017.01.023_bib18","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2017.01.023_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2002796","article-title":"Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T\u00a0cell proliferation","volume":"5","author":"Patsoukis","year":"2012","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ymthe.2017.01.023_bib20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","article-title":"Tumor-specific T\u00a0cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis","volume":"45","author":"Schietinger","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2017.01.023_bib21","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1158\/0008-5472.CAN-06-3974","article-title":"Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus","volume":"67","author":"Diaz","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2017.01.023_bib22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ijrobp.2015.07.2274","article-title":"Definitive management of oligometastatic melanoma in a murine model using combined ablative radiation therapy and viral immunotherapy","volume":"93","author":"Blanchard","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ymthe.2017.01.023_bib23","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/mt.2015.156","article-title":"Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses","volume":"24","author":"Rajani","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.01.023_bib24","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.4049\/jimmunol.0903478","article-title":"Premature terminal exhaustion of Friend virus-specific effector CD8+ T\u00a0cells by rapid induction of multiple inhibitory receptors","volume":"184","author":"Takamura","year":"2010","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2017.01.023_bib25","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-11-0096","article-title":"Anti-TIM3 antibody promotes T\u00a0cell IFN-\u03b3-mediated antitumor immunity and suppresses established tumors","volume":"71","author":"Ngiow","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2017.01.023_bib26","doi-asserted-by":"crossref","first-page":"e0140694","DOI":"10.1371\/journal.pone.0140694","article-title":"TIM-3 suppresses anti-CD3\/CD28-induced TCR activation and IL-2 expression through the NFAT signaling pathway","volume":"10","author":"Tomkowicz","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2017.01.023_bib27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/PPO.0000000000000059","article-title":"Biochemical signaling of PD-1 on T\u00a0cells and its functional implications","volume":"20","author":"Boussiotis","year":"2014","journal-title":"Cancer J."},{"key":"10.1016\/j.ymthe.2017.01.023_bib28","doi-asserted-by":"crossref","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2017.01.023_bib29","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1158\/0008-5472.CAN-13-2908","article-title":"PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8+ T\u00a0cells induced by melanoma vaccines","volume":"74","author":"Fourcade","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2017.01.023_bib30","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1128\/JVI.76.2.895-904.2002","article-title":"Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease","volume":"76","author":"Fernandez","year":"2002","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2017.01.023_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0092-8674(94)90169-4","article-title":"T cell receptor antagonist peptides induce positive selection","volume":"76","author":"Hogquist","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2017.01.023_bib32","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1084\/jem.20030590","article-title":"Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T\u00a0cells","volume":"198","author":"Overwijk","year":"2003","journal-title":"J.\u00a0Exp. Med."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617300606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617300606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T06:28:34Z","timestamp":1717828114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001617300606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1525001617300606"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.01.023","relation":{},"ISSN":["1525-0016"],"issn-type":[{"type":"print","value":"1525-0016"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.01.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017","name":"copyright","label":"Copyright"}]}}